EFFECTS OF STATINS ON PULMONARY HYPERTENSION

他汀类药物对肺动脉高压的影响

• 批准号: 6600353
• 负责人: REDA E GIRGIS
• 金额: $ 13.09万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-13 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6600353
• 关键词: HMG coA reductases; angiogenesis; antihypertensive agents; cell proliferation; drug screening /evaluation; geranyl compound; hemodynamics; laboratory rat; nitric oxide synthase; oxidative stress; oxidoreductase inhibitor; pharmacokinetics; pulmonary hypertension; simvastatin; vascular endothelial growth factors; vascular endothelium; vascular resistance; vascular smooth muscle; vasoconstriction

DESCRIPTION (provided by applicant): The candidate for this mentored clinical scientist development award has a strong clinical interest in pulmonary hypertensive disorders and is committed to a research career in this field. The candidate's institution has a long, rich history of training distinguished clinical and basic scientists and provides an unparalleled environment for academic career development. The sponsor and co-sponsor are internationally acclaimed experts in the pathobiology of pulmonary hypertension (PH). The third member of the Advisory Committee is an expert in pulmonary endothelial cell biology and small G-protein signaling. The candidate will receive closely supervised research training, as well as a carefully selected program of didactic instruction. The research plan will test the hypothesis that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) attenuate pulmonary hypertension. Endothelial dysfunction is a key factor in the excessive vasoconstriction and abnormal vascular wall cell proliferation of severe PH. Statins have been shown to improve several normal endothelial cell functions, independent of their cholesterol lowering effect, through inhibition of small G-protein prenylation. The candidate has obtained preliminary data demonstrating that statins attenuate chronic hypoxic PH in rats. Specific aim #1 will test the ability of statins to attenuate PH and pulmonary vascular remodeling in a rat model of severe PH induced by chronic hypoxia plus vascular endothelial growth factor receptor-2 blockade. This model is characterized prominent endothelial as well smooth muscle cell proliferation, closely resembling human pulmonary arterial hypertension. Specific aim #2 will explore the cellular and molecular mechanisms responsible for the beneficial effect of statin treatment in this model. The long-term objectives of this research are to: 1) probe the cellular transduction mechanisms involved in the effects of statins, 2) to perform translational studies in humans with PH based on these concepts and ultimately, 3) to develop novel therapies for this life-threatening disorder. This award will allow the candidate to develop into a well-trained independent researcher in PH.

描述（由申请人提供）： 该指导临床科学家发展奖的候选人对肺动脉高压疾病有浓厚的临床兴趣，并致力于该领域的研究事业。候选人的机构在培养杰出的临床和基础科学家方面有着悠久而丰富的历史，并为学术职业发展提供了无与伦比的环境。 申办者和共同申办者是国际知名的肺动脉高压（PH）病理生物学专家。 咨询委员会的第三位成员是肺内皮细胞生物学和小G蛋白信号传导方面的专家。 候选人将接受密切监督的研究培训，以及精心挑选的教学指导计划。 该研究计划将测试3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂（他汀类药物）减轻肺动脉高压的假设。 内皮功能障碍是严重PH的过度血管收缩和异常血管壁细胞增殖的关键因素。他汀类药物已被证明通过抑制小G蛋白异戊烯化来改善几种正常内皮细胞功能，而不依赖于其降胆固醇作用。该候选人已获得初步数据，表明他汀类药物可减轻大鼠慢性缺氧PH。 具体目标#1将在慢性缺氧加血管内皮生长因子受体-2阻断诱导的重度PH大鼠模型中测试他汀类药物减弱PH和肺血管重塑的能力。 该模型的特征在于显著的内皮细胞以及平滑肌细胞增殖，非常类似于人肺动脉高压。 具体目标#2将探索负责该模型中他汀类药物治疗的有益作用的细胞和分子机制。 本研究的长期目标是：1）探索他汀类药物作用中涉及的细胞转导机制，2）基于这些概念在PH患者中进行翻译研究，最终，3）为这种危及生命的疾病开发新的治疗方法。 该奖项将使候选人发展成为一个训练有素的独立研究人员在PH。